Editas Medicine (EDIT) CFO tax-related share sale executed under preset plan

Rhea-AI Filing Summary

Editas Medicine, Inc. executive Amy Parison, SVP and Chief Financial Officer, reported the sale of 678 shares of common stock on August 3, 2026 at $2.58 per share. The sale was executed under a Rule 10b5-1 durable automatic sales instruction plan adopted on July 7, 2022 to satisfy tax withholding obligations arising from restricted stock units that vested on August 1, 2026 and was not a discretionary trade. Following this transaction, she directly holds 14,292 shares of Editas Medicine common stock.

Insider Trade Summary 10b5-1

Net Seller: 678 shares

Net Sell 1 txn

Insider Parison Amy

Role SVP, Chief Financial Officer

Sold 678 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	678	$2.58	$2K

Holdings After Transaction: Common Stock — 14,292 shares (Direct)

Footnotes (1)

1. F1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 1, 2026. The sale does not represent a discretionary trade by the Reporting Person.

Key Figures

Shares sold: 678 shares Sale price: $2.58 per share Shares held after sale: 14,292 shares +2 more

5 metrics

Shares sold 678 shares Common stock sold by CFO on August 3, 2026

Sale price $2.58 per share Price for the 678 common shares sold on August 3, 2026

Shares held after sale 14,292 shares Direct holdings of CFO following the reported transaction

Plan adoption date July 7, 2022 Date durable automatic sales instruction plan was adopted

RSU vesting date August 1, 2026 Vesting date that triggered related tax withholding sale

Key Terms

durable automatic sales instruction plan, restricted stock units, tax withholding obligations, Rule 10b5-1

4 terms

durable automatic sales instruction plan regulatory

"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person"

restricted stock units financial

"tax withholding obligations as a result of vesting in restricted stock units on August 1, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"represents the sale of shares by the Issuer necessary to meet tax withholding obligations"

Rule 10b5-1 regulatory

"Transactions were affirmed under a Rule 10b5-1 trading arrangement"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 04:09 PM Accepted by SEC EDGAR 08/05/2026 - 04:07 PM Learn about SEC filing dates

FAQ

What insider transaction did Editas Medicine (EDIT) report for Amy Parison?

Editas Medicine reported that CFO Amy Parison sold 678 shares of common stock on August 3, 2026 at $2.58 per share. The transaction was made under a prearranged Rule 10b5-1 plan and related to tax withholding on vested restricted stock units.

How many Editas Medicine (EDIT) shares did the CFO sell and at what price?

The CFO sold 678 shares of Editas Medicine common stock at $2.58 per share. This sale was classified as an open market or private transaction and tied to tax withholding needs from restricted stock unit vesting.

Does the Editas Medicine (EDIT) Form 4 sale reflect a discretionary trade by the CFO?

No. The filing states the sale does not represent a discretionary trade by the CFO. It was executed under a durable automatic sales instruction plan adopted July 7, 2022, to cover tax withholding on restricted stock units that vested August 1, 2026.

What trading arrangement governed the Editas Medicine (EDIT) CFO’s share sale?

The sale was executed under a Rule 10b5-1 trading arrangement, described as a durable automatic sales instruction plan adopted on July 7, 2022. Such plans prearrange trades, limiting the informational value of the transaction’s timing.

How many Editas Medicine (EDIT) shares does the CFO hold after this Form 4 transaction?

After the reported sale, the CFO directly holds 14,292 shares of Editas Medicine common stock. This post-transaction holding reflects only the position reported in this Form 4 and does not include any unreported future changes.

Why did the Editas Medicine (EDIT) CFO sell shares according to the Form 4 footnote?

According to the footnote, the sale represents shares sold by the issuer to meet tax withholding obligations from restricted stock units that vested on August 1, 2026. It clarifies the transaction was plan-driven rather than discretionary.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parison Amy

(Last) (First) (Middle)

11 HURLEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		S(1)		678	D	$2.58	14,292	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 1, 2026. The sale does not represent a discretionary trade by the Reporting Person.

Remarks:

	/s/ Amy Parison	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)